Abstract
The aim of study effective treatment is to reach the appropriate part of the body and then maintain the required drug concentration at sufficient intervals in order to achieve the clinical therapeutic effect. Problem of the Study. Biological barrier hinders the flow of most drugs from the blood to the focus. Methods of the Study. A novel nanopreparation for inhibition of Epstein‐Barr virus (EBV) was developed based on poly (lactic‐co‐glycolic acid) (PLGA) nanodrug carriers loaded with bicyclic alcohol (BA) and aspirin (Asp) (PLGA‐BA/Asp). Among them, the addition of PLGA can effectively improve the low solubility of BA and poor oral availability. Results have revealed that PLGA‐BA/Asp is a multifunctional therapeutic drug that integrates antivirus, treatment of liver damage, and regulation of the immune system. This discovery provides a new treatment method for the treatment of liver injury in children with EBV infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
